Research Papers: Gerotarget (Focus on Aging):
Leukocyte telomere length and mortality risk in patients with type 2 diabetes
Metrics: PDF 2327 views | HTML 2834 views | ?
Anna Rita Bonfigli1, Liana Spazzafumo2, Francesco Prattichizzo3, Massimiliano Bonafè4, Emanuela Mensà5, Luigina Micolucci6, Angelica Giuliani6, Paolo Fabbietti2, Roberto Testa7, Massimo Boemi8, Fabrizia Lattanzio1 and Fabiola Olivieri5,6
1 Scientific Direction, INRCA-IRCCS National Institute, Ancona, Italy
2 Center of Biostatistics, INRCA-IRCCS National Institute, Ancona, Italy
3 Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Rosselló, Barcelona, Spain
4 Department of Experimental, Diagnostic and Specialty Medicine, DIMES, University of Bologna, Bologna, Italy
5 Center of Clinical Pathology and Innovative Therapy, National Institute INRCA-IRCCS, Ancona, Italy
6 Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy
7 Experimental Models in Clinical Pathology, INRCA-IRCCS National Institute, Ancona, Italy
8 Metabolic Diseases and Diabetology Unit, INRCA-IRCCS National Institute, Ancona, Italy
Anna Rita Bonfigli, email:
Keywords: telomere shortening, type 2 diabetes, mortality, aging, Gerotarget
Received: April 19, 2016 Accepted: July 01, 2016 Published: July 15, 2016
Leukocyte telomere length (LTL) shortening is found in a number of age-related diseases, including type 2 diabetes (T2DM). In this study its possible association with mortality was analyzed in a sample of 568 T2DM patients (mean age 65.9 ± 9 years), who were followed for a median of 10.2 years (interquartile range 2.2). A number of demographic, laboratory and clinical parameters determined at baseline were evaluated as mortality risk factors. LTL was measured by quantitative real-time PCR and reported as T/S (telomere-to-single copy gene ratio). Age, gender, creatinine, diabetes duration at baseline, and LTL were significantly different between T2DM patients who were dead and alive at follow-up. In the Cox regression analysis adjusted for the confounding variables, shorter LTL, older age, and longer disease duration significantly increased the risk of all-cause mortality (HR = 3.45, 95%CI 1.02-12.5, p = 0.004). Kaplan-Maier analysis also found a different cumulative mortality risk for patients having an LTL shorter than the median (T/S ≤0.04) and disease duration longer than the median (>10 years) (log-rank = 11.02, p = 0.011). Time-dependent mortality risk stratification showed that T2DM duration and LTL combined was a fairly good predictor of mortality over the first 76 months of follow-up.
In conclusion, LTL combined with clinical parameters can provide additive prognostic information on mortality risk in T2DM patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.